Literature DB >> 28640673

The End of Written Informed Consent for HIV Testing: Not With a Bang but a Whimper.

Ronald Bayer1, Morgan Philbin1, Robert H Remien1.   

Abstract

In 2014, only two states in the United States still mandated specific written informed consent for HIV testing and, after years of controversy, New York ended this requirement, leaving only Nebraska. New York's shift to opt-out testing meant that a singular feature of what had characterized the exceptionalism surrounding HIV testing was eliminated. We trace the history of debates on written informed consent nationally and in New York State. Over the years of dispute from when HIV testing was initiated in 1985 to 2014, the evidence about the benefits and burdens of written informed consent changed. Just as important was the transformation of the political configuration of HIV advocacy and funding, both nationwide and in New York State. What had for years been the subject of furious debate over what a rational and ethical screening policy required came to an end without the slightest public protest. (Am J Public Health. 2017;107:1259-1265. doi:10.2105/AJPH.2017.303819).

Mesh:

Year:  2017        PMID: 28640673      PMCID: PMC5508137          DOI: 10.2105/AJPH.2017.303819

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  7 in total

1.  Public health policy and the AIDS epidemic. An end to HIV exceptionalism?

Authors:  R Bayer
Journal:  N Engl J Med       Date:  1991-05-23       Impact factor: 91.245

2.  Applying public health principles to the HIV epidemic.

Authors:  Thomas R Frieden; Moupali Das-Douglas; Scott E Kellerman; Kelly J Henning
Journal:  N Engl J Med       Date:  2005-12-01       Impact factor: 91.245

3.  Changing the paradigm for HIV testing--the end of exceptionalism.

Authors:  Ronald Bayer; Amy L Fairchild
Journal:  N Engl J Med       Date:  2006-08-17       Impact factor: 91.245

4.  Evaluating the New York State 2010 HIV testing law amendments: context, challenges, and conclusions.

Authors:  Guthrie S Birkhead; Daniel A OʼConnell; Shu-Yin J Leung; Lou C Smith
Journal:  J Acquir Immune Defic Syndr       Date:  2015-01-01       Impact factor: 3.731

5.  HIV antibody screening. An ethical framework for evaluating proposed programs.

Authors:  R Bayer; C Levine; S M Wolf
Journal:  JAMA       Date:  1986-10-03       Impact factor: 56.272

6.  Evidence and the Politics of Deimplementation: The Rise and Decline of the "Counseling and Testing" Paradigm for HIV Prevention at the US Centers for Disease Control and Prevention.

Authors:  David Merritt Johns; Ronald Bayer; Amy L Fairchild
Journal:  Milbank Q       Date:  2016-03       Impact factor: 4.911

7.  Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings.

Authors:  Bernard M Branson; H Hunter Handsfield; Margaret A Lampe; Robert S Janssen; Allan W Taylor; Sheryl B Lyss; Jill E Clark
Journal:  MMWR Recomm Rep       Date:  2006-09-22
  7 in total
  4 in total

1.  State Trends in HIV Testing Among US Adults Aged 18-64 Years, 2011-2017.

Authors:  Amy Krueger; Christopher Johnson; Janet Heitgerd; Deesha Patel; Norma Harris
Journal:  Public Health Rep       Date:  2020-06-24       Impact factor: 2.792

2.  Trends in HIV Testing Among US Adults, Aged 18-64 Years, 2011-2017.

Authors:  Deesha Patel; Christopher H Johnson; Amy Krueger; Barbara Maciak; Lisa Belcher; Norma Harris; Elizabeth A DiNenno
Journal:  AIDS Behav       Date:  2020-02

3.  Reducing False-Positive Results With Fourth-Generation HIV Testing at a Veterans Affairs Medical Center.

Authors:  Jeffrey Petersen; Maria Monteiro; Sharvari Dalal; Darshana Jhala
Journal:  Fed Pract       Date:  2021-05

4.  Comparing Routine HIV and Hepatitis C Virus Screening to Estimate the Effect of Required Consent on HIV Screening Rates Among Hospitalized Patients.

Authors:  Uriel R Felsen; Aileen Tlamsa; Lorlette Moir; Shuchin Shukla; Devin Thompson; Jeffrey M Weiss; Moonseong Heo; Alain H Litwin
Journal:  Public Health Rep       Date:  2021-03-05       Impact factor: 2.792

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.